Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium lactate + calcium gluconate + calcium hydrogen phosphate is an approved oral combination mineral supplement developed by Menovo Tiankang. Each chewable tablet contains 50 mg of each of the three calcium salts, providing a total of approximately 22.6 mg of elemental calcium. As an over-the-counter (OTC) medication, it is indicated for the prevention and treatment of calcium deficiency-related conditions, including osteoporosis, rickets, bone hypoplasia, and tetany (hand and foot convulsions). It is also used as a calcium supplement for pregnant, lactating, and menopausal women. The drug works by delivering calcium ions to the body, which are essential for bone formation, nerve impulse transmission, and muscle contraction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium lactate + calcium gluconate + calcium hydrogen phosphate.